Previous 10 |
home / stock / akblf / akblf news
ROUND ROCK, Texas , June 17, 2020 /PRNewswire/ -- ALK ( ALKB:DC / OMX:ALK B / AKABY / AKBLF ) a global, research-driven pharmaceutical company that focuses on the prevention, diagnosis and treatment of allergies, announced today the signing of an exclusive agreement with Otonomy...
ALK-Abelló A/S ( OTCPK:AKBLF ): FY GAAP EPS of -DKK4.60. More news on: ALK-Abelló A/S, ALK-Abelló A/S, Earnings news and commentary, Healthcare stocks news, Read more ...
ROUND ROCK, Texas , Nov. 8, 2019 /PRNewswire/ -- ALK ( ALKB:DC / OMX: ALK B / AKABY / AKBLF ), a global, research-driven pharmaceutical company that focuses on the prevention, diagnosis and treatment of allergies, announced new Phase 3 data today on its sublingual allergy immunothera...
ROUND ROCK, Texas , Sept. 28, 2019 /PRNewswire/ -- ALK ( ALKB:DC / OMX: ALK B / AKABY / AKBLF ) is pleased to join several organizations as a sponsor of the third annual National Penicillin Allergy Day, an awareness day to help educate the community on penicillin allergies and t...
HØRSHOLM, Denmark , June 3, 2019 /PRNewswire/ -- Zydis ® freeze-dried tablet technology used in ALK's SLIT-tablet range makes them faster dissolving than conventional compressed sublingual tablets in in-vitro testing. Resulting in rapid and predictable release of the ac...
- Easy to measure biomarkers could identify a group of patients who benefit even more from ACARIZAX® treatment of house dust mite (HDM)-induced allergic asthma - Early identification of patients would allow earlier treatment intervention - With its HDM SLIT-tablet, ALK is well-plac...
ALK-Abelló A/S ( OTCPK:AKBLF ): Q1 net income of DKK89M More news on: ALK-Abelló A/S, ALK-Abelló A/S, Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Alk-Abello A/S Company Name:
AKBLF Stock Symbol:
OTCMKTS Market:
ALK ( ALKB:DC / OMX: ALK B / AKBLF ): The Annual General Meeting of ALK-Abelló A/S will take place on Thursday, 14 March 2024 at 4:00 PM (CET) at ALK-Abelló A/S, 1 Bøge Allé, 2970 Hørsholm, Denmark. The agenda of the meeting including the complete proposals from the B...
08 February 2024 ALK’s ( ALKB:DC / OMX: ALK B / AKBLF ) Board of Directors has approved the company’s 2023 annual report. Following a robust performance in Q4, full-year results were in line with the latest outlook. ALK expects to continue its growth trajectory and earning...
The trial now progresses into its second part, expected to complete later in 2024. ALK to submit a protocol amendment for Phase 1-2 efficacy trial extension. ALK ( ALKB:DC / OMX: ALK B / AKBLF ) announced today that it has completed the first part of its phase 1 clinical trial...